Omeros suspends Phase II Huntington's trial

Omeros Corp. (NASDAQ:OMER) was off $1.70 (12%) to $12.12 on Tuesday after suspending a Phase II trial of OMS824 to treat Huntington's disease (HD).

Omeros' decision followed an unspecified observation in "several" rats receiving the maximum dose of OMS824, whose drug exposure was at an unspecified multiple of that observed in human HD patients. Omeros said it did not observe comparable results in nonhuman primates with drug exposures comparable to those in the rat study. ...